Antigen-specific immunomodulation via altered peptide ligands

被引:55
作者
Bielekova, B [1 ]
Martin, R [1 ]
机构
[1] NINCDS, Cellular Immunol Sect, Neuroimmunol Branch, Bethesda, MD 20892 USA
来源
JOURNAL OF MOLECULAR MEDICINE-JMM | 2001年 / 79卷 / 10期
关键词
altered peptide ligand; immunotherapy; autoimmunity;
D O I
10.1007/s001090100259
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
An important subgroup of human cellular receptors uses peptides as signaling molecules. Modifications of these signaling peptides, usually by amino acid substitutions in crucial receptor contact sites (i.e., altered peptide ligands, APLs), is an approach for highly selective and specific modulation of the receptor function. One of the major applications of APLs is immunology, where APLs have been examined for therapeutic modulation of T cell function, both for diseases characterized by unwanted activation of T cells (e.g., autoimmune diseases) and for disorders with suboptimal T cell activation (e.g., immunotherapy of cancers and infectious disorders). APLs also occur in vivo, for example, as escape mutants of infectious agents, and play an important role in thymic positive selection. We summarize current knowledge of the basic mechanisms of the effects of APLs with special focus on T cell receptor signaling and the use of APLs for the treatment of autoimmune diseases.
引用
收藏
页码:552 / 565
页数:14
相关论文
共 81 条
  • [1] Modulation of chromatin structure regulates cytokine gene expression during T cell differentiation
    Agarwal, S
    Rao, A
    [J]. IMMUNITY, 1998, 9 (06) : 765 - 775
  • [2] High frequency of autoreactive myelin proteolipid protein-specific T cells in the periphery of naive mice: Mechanisms of selection of the self-reactive repertoire
    Anderson, AC
    Nicholson, LB
    Legge, KL
    Turchin, V
    Zaghouani, H
    Kuchroo, VK
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (05) : 761 - 770
  • [3] Negative selection during the peripheral immune response to antigen
    Anderton, SM
    Radu, CG
    Lowrey, PA
    Ward, ES
    Wraith, DC
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (01) : 1 - 11
  • [4] Ausubel LJ, 1997, J IMMUNOL, V159, P2502
  • [5] Cross-reactivity of T-cell clones specific for altered peptide ligands of myelin basic protein
    Ausubel, LJ
    Bieganowska, KD
    Hafler, DA
    [J]. CELLULAR IMMUNOLOGY, 1999, 193 (01) : 99 - 107
  • [6] Conversion of a T cell antagonist into an agonist by repairing a defect in the TCR/peptide/MHC interface: Implications for TCR signaling
    Baker, BM
    Gagnon, SJ
    Biddison, WE
    Wiley, DC
    [J]. IMMUNITY, 2000, 13 (04) : 475 - 484
  • [7] FREQUENCY OF ANTINUCLEAR ANTIBODIES IN MULTIPLE-SCLEROSIS
    BARNED, S
    GOODMAN, AD
    MATTSON, DH
    [J]. NEUROLOGY, 1995, 45 (02) : 384 - 385
  • [8] Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand
    Bielekova, B
    Goodwin, B
    Richert, N
    Cortese, I
    Kondo, T
    Afshar, G
    Gran, B
    Eaton, J
    Antel, J
    Frank, JA
    McFarland, HF
    Martin, R
    [J]. NATURE MEDICINE, 2000, 6 (10) : 1167 - 1175
  • [9] Preferential expansion of autoreactive T lymphocytes from the memory T-cell pool by IL-7
    Bielekova, B
    Muraro, PA
    Golestaneh, L
    Pascal, J
    McFarland, HF
    Martin, R
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 1999, 100 (1-2) : 115 - 123
  • [10] Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein
    Brocke, S
    Gijbels, K
    Allegretta, M
    Ferber, I
    Piercy, C
    Blankenstein, T
    Martin, R
    Utz, U
    Karin, N
    Mitchell, D
    Veromaa, T
    Waisman, A
    Gaur, A
    Conlon, P
    Ling, N
    Fairchild, PJ
    Wraith, DC
    OGarra, A
    Fathman, CG
    Steinman, L
    [J]. NATURE, 1996, 379 (6563) : 343 - 346